Active Oncology Clinical Trials October 2018

BREAST

ADJUVANT:

S1207: A Phase III Randomized, Placebo –Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and Her2/Neu Negative Breast Cancer e³ Breast Cancer Study- evaluating everolimus with endocrine therapy

Learn More: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

CK-SAPBI: CyberKnife Stereotactic Accelerated Partial Breast Irradiation Registry

Learn More: A Multi-Institutional Registry for CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)

DOTAN STUDY: Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient via a Provider Didactic Intervention

Learn More: Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient

A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Learn More: Breast Cancer WEight Loss Study (BWEL Study)

GASTROINTESTINAL

ADVANCED RECTAL:

N1048: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Learn More: PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
HEAD AND NECK

EA3132  Phase II Randomized Trial of Radiotherapy with or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
Learn More:  Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

MULTIPLE MYELOMA

BMS CA204008 ST:  Prospective Research Assessment in Multiple Myeloma: an OBServationaL Evaluation (PREAMBLE)

E1A11  Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURATION Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Learn More:  Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

OBSERVATIONAL PATIENT REGISTRY

RSSearch Registry:  The RSSearch® Patient Registry is an international multi-year database designed to track utilization of all available stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) systems, treatment practices and outcomes to help determine, over time, the most effective use of the these systems in management of patients with life threatening tumors and other diseases

THORACIC

S1400:  Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Learn More:  Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

S1400F  A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1-L1 Resistant Stage IV Squamous Cell Lung Cancer(Lung-Map Non-Match Sub-Study)
Learn More:  Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
S1400K  A Phase II Study of ABBV-399 in Patients with C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)
Lung-MAP S1400K: c-MET Positive

A151216:  Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Learn More:  Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

- E4512:  A Phase III Double-Blind Trial of Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Learn More:  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

- EA5142:  Adjuvant Nivolumab in Resected Lung Cancer (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancer
Learn More:  Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer

- A081105:  Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Learn More:  Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

EA5152:  A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients with Previously Treated Non-Squamous NSCLC
Learn More:  Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

EA5161  Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Learn More:  Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Lung Cancer
PANCREATIC

A021501: Preoperative Extended Chemotherapy vs. Chemotherapy plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

Learn More: Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

RARE TUMORS

S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Learn More: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors